




MANHATTAN SCIENTIFICS, INC.

OTC ► BB MHTX

The Chrysler Building 405 Lexington Avenue, 32nd floor • New York • NY • 10174 • Tel: (212) 551-0577 <http://www.mhtx.com>

| | |
|-----------------------------|--|
| IR & PR CONTACTS | <ul style="list-style-type: none"> ► Kelly Black: 480.649.8224 kblack@premierfundingservice.com ► Marvin Maslow, Founder: 917.923.3300 Marvin@MarvinMaslow.com ► Hawk Associates http://www.hawkassociates.com |
| EXEC CONTACT | <ul style="list-style-type: none"> ► CEO: Manny Tsoupanarias: 918.919.0370 mannyt@mhtx.com |
| TECHNICAL CONTACT | <ul style="list-style-type: none"> ► Terry Lowe, Ph. D 505.670.8755 tlowe@metallicum.com |
| INDUSTRIAL PARTNER | <ul style="list-style-type: none"> ► Carpenter Technology Corporation http://www.cartech.com/ NYSE: CRS. Tim Armstrong, PhD 610.208.3923 tarmstrong@cartech.com |



MANHATTAN SCIENTIFICS owns the exclusive, perpetual USA license to a family of patents which will enable the marketing of super strong, ultra light-weight “nanostructured” metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union.

These new metals defy the rules that have limited the capability of all other metals. (Please see the video on the Company’s website: www.MHTX.com, go to “Media”). The Company’s process will enable double-strength metals and alloys, i.e. aluminum as strong as steel, with a fraction of the weight.



The Company’s nano-titanium product, now licensed to its major industrial partner, Carpenter Technology Corporation (NYSE: CRS) will enable a new family of medical devices and prosthetics with capability of bonding to human bone tissue up to 20x faster and stronger than present day products.

In December, 2008, the FDA approved the use of the Company’s nano-titanium alloy with dental implants. These implants are manufactured in the Company’s affiliated factory in Albuquerque, NM. (See press release of 12/09/08)

Nanostructured cardio vascular stents will be up to 10x thinner, less prone to failure, easier to manufacture, and easier for surgeons to place in our bodies. For bone implants, the MHTX process called, “Nano structuring”, applicable to virtually ALL metals, alters the materials already in use and approved by the FDA so that they sustain twice the load capacity and integrate with bone up to 20 times faster than conventional prosthetics. FDA approval will be required for each medical application.

Manhattan Scientifics & Carpenter Technology Corp. are together exploring the medical, sports and aerospace industries and other down-the-road applications targeting the transportation industry where doubly strong, lightweight materials hold the promise of dramatically and positively impacting fuel economy and performance of any vehicle that moves, i.e. cars, ships, trucks, aircraft, trains, etc. i.e. by removing up to 500 lbs from a 4-door sedan, the weight of an entire family, or by putting airplanes on a diet, removing thousands of pounds while maintaining full structural strength.


Company Description & History

In its early years, Manhattan Scientifics’ market cap reached \$900 million as its share price approached \$9.00. These lofty heights ended when the Nasdaq bubble broke in year 2000. Today MHTX sells at a fraction of its former levels, yet the Company is substantially stronger than at anytime during its history.

Management is dedicated to restore shareholder value. The MHTX business model, acquiring, patenting, demonstrating and licensing to a major industrial deep-pocket partner has been proven with the culmination of the Carpenter relationship in mid 2009. The Company will continue to incubate & commercialize world-changing technologies bringing product to market and profit to its shareholders.

Below one can see the 10 year historical chart and the current 1-year chart of MHTX:

10 Year Historical Chart



1 Year Current Chart



Executive Summary

Manhattan Scientifics (OTC BB: MHTX) was formed to commercialize disruptive technologies sourced at the U.S. government nuclear labs, i.e. The Los Alamos & The Sandia National Laboratories in close proximity to the Company's operations in Northern New Mexico.

The Company's business model capitalizes on inventions and technology from which profits could be earned primarily through licensing. MHTX is dedicated to earning profit for its 8,600 owner-shareholders by identifying, developing, patenting, supporting and marketing technical innovation by harvesting top technology talent to bring game-changing products to market.

Our Science Team includes technology leaders, i.e. Dr. Martin Cooper, inventor of the cell phone, Dr. Arthur Kaufman, co-founder of H-Power, Donald Sandstrom, former Division Leader, Materials Science, LANL, Dr. Terry Lowe, former CEO of Technanogy to guide our introduction of new technological innovations. The Company's acquisition of Metallicum Inc. in 2008 marked a sea-change in the exploration of commercial applications for a new generation of metals designed to transform the biomedical device industry and the transportation industry, in much the same way as our Martin Cooper changed the telephone from the original Alexander Graham Bell invention.

Management Team & Company Contacts

- CHAIRMAN AND CEO** ▶ Emmanuel Tsoupanarias
- FOUNDER & CHAIRMAN EMERITUS** ▶ Marvin Maslow
- DIRECTOR** ▶ Leonard Friedman, Esq.
- DIRECTOR** ▶ Frank Georgiou
- DIRECTOR** ▶ Chris Theoharis

SECURITIES COUNSEL ▶ Peter DiChiara, Esq.,
212-930-9700, Sichenzia Ross Friedman Ference,
62 Broadway, NYC 10006

PATENT COUNSEL ▶ Gerald Grafe, Esq.
Gerald@HiseyGrafe.com

AUDITOR: PMB Helin Donovan (509) 747-0468

TRANSFER AGENT: Interwest Securities (801) 272-9294

Science and Technology Committee

Dr. Martin Cooper, inventor of the cellular telephone.

Dr. Arthur Kaufman, Co-founder of H-Power

Dr. Terry Lowe, Chief Scientist, founder, Metallicum

Dr. Henry Rack-Material Scientist

Donald J. Sandstrom, Division Leader, LANL

The foregoing document contains forward-looking statements which are subject to risk and uncertainty which may be beyond the company's control.